サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1426453

悪性黒色腫治療の世界市場レポート 2024

Malignant Melanoma Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
悪性黒色腫治療の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

悪性黒色腫治療の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には10.8%の年間複合成長率（CAGR）で108億5,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、個別化医療、世界の健康への取り組み、ゲノムプロファイリングの拡大、価値ベースのヘルスケアモデルの採用、患者中心のアプローチに起因すると考えられます。予測期間中に予想される主な動向には、人工知能（AI）の統合、早期発見技術の進歩、現実世界の証拠とデータ分析の利用、精密医療の統合、併用療法の探索などが含まれます。

予想される紫外線（UV）への曝露量の増加により、悪性黒色腫治療市場の拡大が促進されると予想されます。紫外線は、可視光線よりも波長が短く、X線よりも長い電磁放射線の一種であり、悪性黒色腫の発生に大きな影響を与えます。特に太陽からのUVA（315～400 nm）およびUVB（280～315 nm）放射線への曝露は、皮膚細胞のDNA損傷を引き起こし、制御不能な細胞増殖や腫瘍形成を引き起こす突然変異を引き起こす可能性があります。米国に本拠を置く環境保護庁の2021年の報告書によると、紫外線への過度の曝露は、2021年に10万6,000件以上の新たな黒色腫症例を引き起こすと予測されており、これは2020年の数字を約6,000件上回っています。したがって、紫外線への曝露量の増加は、悪性黒色腫治療市場の成長の主要な推進力となります。

黒色腫の発生率の上昇により、悪性黒色腫治療市場の成長が促進されると予想されます。黒色腫は、色素生成を担うメラノサイトに由来する皮膚がんの一種であり、多くの場合、外科的腫瘍除去を伴う治療が必要です。がんの進行度や程度に応じて、免疫療法や標的療法などの追加療法が推奨される場合があります。米国がん協会の2023年1月の予測によると、新たな黒色腫症例は約97,610例、男性では約58,120例、女性では39,490例になると予想されています。黒色腫による推定死亡者数は約7,990人で、そのうち約5,420人が男性、2,570人が女性です。したがって、黒色腫の発生率の増加は、悪性黒色腫治療市場の成長の重要な推進力です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の悪性黒色腫治療市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 免疫療法
  • 放射線治療
  • 化学療法
  • その他の治療法
  • 世界の悪性黒色腫治療市場、疾患別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 黒子悪性黒色腫
  • 末端黒子黒色腫
  • 結節性黒色腫
  • 表在拡大型黒色腫
  • 世界の悪性黒色腫治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 専門クリニック
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の悪性黒色腫治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の悪性黒色腫治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 悪性黒色腫治療市場の競合情勢
  • 悪性黒色腫治療市場の企業プロファイル
    • Johnson &Johnson Private Limited
    • Pfizer Inc.
    • Hoffmann-La Roche AG
    • Bayer AG
    • Novartis AG

第31章 その他の大手および革新的な企業

  • Merck &Co. Inc.
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • AstraZeneca plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Amgen Inc.
  • Daiichi Sankyo Company Limited
  • Mylan NV
  • Chugai Pharmaceutical Co. Ltd.
  • Sun Pharmaceutical Industries Limited
  • bioMerieux SA
  • Ono Pharmaceutical Co. Ltd.
  • Exelixis Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13465

Malignant melanoma treatment involves medical interventions and therapies aimed at managing and potentially curing malignant melanoma, a type of skin cancer originating from melanocytes, the cells responsible for producing the skin pigment melanin. The treatment of malignant melanoma provides several critical advantages for the well-being and potential recovery of individuals diagnosed with this aggressive form of skin cancer.

The primary treatments for malignant melanoma include immunotherapy, radiation therapy, chemotherapy, and others. Immunotherapy is a medical treatment that utilizes the body's own immune system to combat diseases, including certain types of cancer. Indicated for treating lentigo malignant melanoma, acral lentiginous melanoma, nodular melanoma, and superficial spreading melanoma, these treatments are administered by various end-users such as hospitals, specialty clinics, and others.

The malignant melanoma treatment market research report is one of a series of new reports from The Business Research Company that provides malignant melanoma treatment market statistics, including malignant melanoma treatment industry global market size, regional shares, competitors with a malignant melanoma treatment market share, detailed malignant melanoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the malignant melanoma treatment industry. This malignant melanoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The malignant melanoma treatment market size has grown rapidly in recent years. It will grow from $6.44 billion in 2023 to $7.21 billion in 2024 at a compound annual growth rate (CAGR) of 12.0%. The growth observed during the historical period can be attributed to targeted therapies, increased patient awareness and education, collaborative research initiatives, and regulatory approvals.

The malignant melanoma treatment market size is expected to see rapid growth in the next few years. It will grow to $10.85 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The anticipated growth in the forecast period can be attributed to personalized medicine, global health initiatives, expanded genomic profiling, the adoption of value-based healthcare models, and patient-centric approaches. Major trends expected during the forecast period include the integration of artificial intelligence (AI), advancements in early detection technologies, the utilization of real-world evidence and data analytics, the integration of precision medicine, and the exploration of combination therapies.

The anticipated increase in exposure to ultraviolet (UV) radiation is expected to drive the expansion of the malignant melanoma treatment market. UV radiation, an electromagnetic radiation type with a wavelength shorter than visible light but longer than X-rays, significantly influences the development of malignant melanoma. Exposure to UVA (315-400 nm) and UVB (280-315 nm) radiation, particularly from the sun, can lead to DNA damage in skin cells, causing mutations that result in uncontrolled cell growth and tumor formation. According to a 2021 report from the US-based Environmental Protection Agency, overexposure to UV radiation is predicted to contribute to more than 106,000 new cases of melanoma in 2021, surpassing the 2020 figures by around 6,000 cases. Consequently, the increasing exposure to UV radiation is a key driver of growth for the malignant melanoma treatment market.

The rising incidence of melanoma is expected to fuel the growth of the malignant melanoma treatment market. Melanoma, a type of skin cancer originating in melanocytes responsible for pigment production, often requires treatment involving surgical tumor removal. Additional therapies, such as immunotherapy or targeted therapy, may be recommended based on the cancer's stage and extent. According to the American Cancer Society's projections for January 2023, around 97,610 new cases of melanoma are expected, with approximately 58,120 cases in men and 39,490 cases in women. The estimated number of fatalities due to melanoma is approximately 7,990, with around 5,420 being men and 2,570 being women. Hence, the increasing incidence of melanoma is a significant driver of growth for the malignant melanoma treatment market.

The high cost of cancer treatment is anticipated to hinder the growth of the malignant melanoma treatment market. The financial burden associated with cancer treatment, including surgeries, radiation therapy, chemotherapy, and immunotherapy, leads to substantial out-of-pocket expenses, impacting patient access to treatment. This economic strain may result in delayed or deferred treatment, especially for individuals lacking sufficient insurance coverage. The high cost can limit access to advanced therapies, potentially affecting treatment outcomes for cancer patients. The American Cancer Society Cancer Action Network reported that survivor expenses, including follow-up care and addressing the late and long-term effects of cancer, amounted to $1,881 per survivor in December 2022. Moreover, 51% of surveyed patients reported incurring medical debt related to cancer. Therefore, the high cost of cancer treatment poses a challenge to the malignant melanoma treatment market's growth.

Prominent players in the malignant melanoma treatment market are strategically focused on the development and approval of innovative drugs to fortify their market position. The increasing demand for more effective and safer treatments has led to a surge in drug approvals for malignant melanoma treatment, exemplified by Opdualag. This novel therapeutic option is a fixed-dose combination featuring two immunotherapy drugs, nivolumab and relatlimab-rmbw, designed to address unresectable or metastatic melanoma. Bristol Myers Squibb, a leading US-based pharmaceutical company, obtained approval for Opdualag from the US Food and Drug Administration in March 2022. Administered as a single intravenous infusion, Opdualag represents a first-in-class treatment, providing a groundbreaking approach for adult and pediatric patients aged 12 or older with metastatic or unresectable melanoma. Relatlimab-rmbw, a human IgG4 monoclonal antibody targeting the LAG-3 receptor, complements nivolumab in this fixed-dose combination. Opdualag's successful launch marks a significant addition to Bristol Myers Squibb's portfolio of cancer treatments, contributing to the company's overall growth.

In June 2022, Germany-based biotechnology firm Immatics N.V. joined forces with Bristol Myers Squibb to pioneer gamma delta allogeneic cell therapy programs. This collaboration is geared towards advancing cutting-edge cancer immunotherapies with the potential to revolutionize the treatment landscape for various cancers, including malignant melanoma. Bristol Myers Squibb, as a US-based pharmaceutical company, remains steadfast in its commitment to discovering, developing, and delivering innovative medicines to patients grappling with serious diseases, with a particular focus on advancing treatments for melanoma. The collaboration with Immatics N.V. underscores the company's dedication to advancing the field of cancer immunotherapy and exploring new avenues for enhanced treatment modalities.

Major companies operating in the malignant melanoma treatment market report are Johnson & Johnson Private Limited, Pfizer Inc., Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Mylan N.V., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, bioMerieux SA, Ono Pharmaceutical Co. Ltd., Exelixis Inc., Array BioPharma Inc., Pierre Fabre Group, Clinigen Group, Iovance Biotherapeutics Inc., X4 Pharmaceuticals Inc., Mirati Therapeutics Inc., Moleculin Biotech Inc., Polynoma LLC, Enzon Pharmaceuticals Inc., Northwest Biotherapeutics Inc.

North America was the largest region in the malignant melanoma treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant melanoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the malignant melanoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The malignant melanoma treatment market consists of revenues earned by entities by providing services such as diagnosis and staging services, surgical services, medical treatments, genetic counseling, aesthetic services, and cosmetic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant melanoma treatment market also includes sales of aldesleukin, binimetinib, braftovi (encorafenib), cobimetinib fumarate, cotellic (cobimetinib fumarate), dabrafenib mesylate, dacarbazine, and encorafenib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Malignant Melanoma Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on malignant melanoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for malignant melanoma treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The malignant melanoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Treatment: Immunotherapy; Radiation Therapy; Chemotherapy; Other Treatments
  • 2) By Disease Type: Lentigo Maligna Melanoma; Acral Lentiginous Melanoma; Nodular Melanoma; Superficial Spreading Melanoma
  • 3) By End-User: Hospitals; Specialty clinics; Other End Users
  • Companies Mentioned: Johnson & Johnson Private Limited; Pfizer Inc.; Hoffmann-La Roche AG; Bayer AG; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Malignant Melanoma Treatment Market Characteristics

3. Malignant Melanoma Treatment Market Trends And Strategies

4. Malignant Melanoma Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Malignant Melanoma Treatment Market Size and Growth

  • 5.1. Global Malignant Melanoma Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Malignant Melanoma Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Malignant Melanoma Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Malignant Melanoma Treatment Market Segmentation

  • 6.1. Global Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Immunotherapy
  • Radiation Therapy
  • Chemotherapy
  • Other Treatments
  • 6.2. Global Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lentigo Maligna Melanoma
  • Acral Lentiginous Melanoma
  • Nodular Melanoma
  • Superficial Spreading Melnoma
  • 6.3. Global Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Other End Users

7. Malignant Melanoma Treatment Market Regional And Country Analysis

  • 7.1. Global Malignant Melanoma Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Malignant Melanoma Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Malignant Melanoma Treatment Market

  • 8.1. Asia-Pacific Malignant Melanoma Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Malignant Melanoma Treatment Market

  • 9.1. China Malignant Melanoma Treatment Market Overview
  • 9.2. China Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Malignant Melanoma Treatment Market

  • 10.1. India Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Malignant Melanoma Treatment Market

  • 11.1. Japan Malignant Melanoma Treatment Market Overview
  • 11.2. Japan Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Malignant Melanoma Treatment Market

  • 12.1. Australia Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Malignant Melanoma Treatment Market

  • 13.1. Indonesia Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Malignant Melanoma Treatment Market

  • 14.1. South Korea Malignant Melanoma Treatment Market Overview
  • 14.2. South Korea Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Malignant Melanoma Treatment Market

  • 15.1. Western Europe Malignant Melanoma Treatment Market Overview
  • 15.2. Western Europe Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Malignant Melanoma Treatment Market

  • 16.1. UK Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Malignant Melanoma Treatment Market

  • 17.1. Germany Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Malignant Melanoma Treatment Market

  • 18.5. France Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.6. France Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.7. France Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Malignant Melanoma Treatment Market

  • 19.9. Italy Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Malignant Melanoma Treatment Market

  • 20.13. Spain Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Malignant Melanoma Treatment Market

  • 21.1. Eastern Europe Malignant Melanoma Treatment Market Overview
  • 21.2. Eastern Europe Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Malignant Melanoma Treatment Market

  • 22.1. Russia Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Malignant Melanoma Treatment Market

  • 23.1. North America Malignant Melanoma Treatment Market Overview
  • 23.2. North America Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Malignant Melanoma Treatment Market

  • 24.1. USA Malignant Melanoma Treatment Market Overview
  • 24.2. USA Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Malignant Melanoma Treatment Market

  • 25.1. Canada Malignant Melanoma Treatment Market Overview
  • 25.2. Canada Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Malignant Melanoma Treatment Market

  • 26.1. South America Malignant Melanoma Treatment Market Overview
  • 26.2. South America Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Malignant Melanoma Treatment Market

  • 27.1. Brazil Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Malignant Melanoma Treatment Market

  • 28.1. Middle East Malignant Melanoma Treatment Market Overview
  • 28.2. Middle East Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Malignant Melanoma Treatment Market

  • 29.1. Africa Malignant Melanoma Treatment Market Overview
  • 29.2. Africa Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Malignant Melanoma Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Malignant Melanoma Treatment Market Competitive Landscape
  • 30.2. Malignant Melanoma Treatment Market Company Profiles
    • 30.2.1. Johnson & Johnson Private Limited
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Pfizer Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Hoffmann-La Roche AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bayer AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Malignant Melanoma Treatment Market Other Major And Innovative Companies

  • 31.1. Merck & Co. Inc.
  • 31.2. GlaxoSmithKline plc
  • 31.3. Bristol-Myers Squibb Company
  • 31.4. Sanofi S.A.
  • 31.5. AstraZeneca plc
  • 31.6. Takeda Pharmaceutical Company Limited
  • 31.7. Eli Lilly and Company
  • 31.8. Amgen Inc.
  • 31.9. Daiichi Sankyo Company Limited
  • 31.10. Mylan N.V.
  • 31.11. Chugai Pharmaceutical Co. Ltd.
  • 31.12. Sun Pharmaceutical Industries Limited
  • 31.13. bioMerieux SA
  • 31.14. Ono Pharmaceutical Co. Ltd.
  • 31.15. Exelixis Inc.

32. Global Malignant Melanoma Treatment Market Competitive Benchmarking

33. Global Malignant Melanoma Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Malignant Melanoma Treatment Market

35. Malignant Melanoma Treatment Market Future Outlook and Potential Analysis

  • 35.1 Malignant Melanoma Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Malignant Melanoma Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Malignant Melanoma Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer